Serum Nesfatin-1 Levels Research Articles

Comparison of Serum Nesfatin-1 and Visfatin Levels Between Patients with Rheumatoid Arthritis and Healthy Controls

Even though elevated nesfatin-1 levels were reported in patients with rheumatoid arthritis (RA) previously, the possible role of body mass index (BMI) was not excluded. The aim of the present study was to compare serum nesfatin-1 and visfatin levels between patients with RA and healthy controls who have normal BMI values (18.50.05). It seems that nesfatin-1 levels are significantly higher in RA patients compared to healthy peers. However, nesfatin-1 levels were not found related to disease activity.

Relationship of Serum Nesfatin-1 and Insulin-Like Growth Factor-1 Levels with Adverse Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome.

To investigate the relationship between serum nesfatin-1 and insulin-like growth factor-1 (IGF-1) levels and adverse pregnancy outcomes (APOs) in patients with polycystic ovary syndrome (PCOS). Observational study. Place and Duration of the Study: The study was performed from June 2021 to 2023 in the General Gynaecology section at the Maternity & Child Care Center of Qinhuangdao, Hebei, China. A total of 120 pregnant women with PCOS were divided into the control and study groups. The control group consisted of 70 pregnant women who successfully delivered healthy newborns, whereas the study group included 50 pregnant women who experienced APOs. The serum nesfatin-1 and IGF-1 levels in both groups were measured upon admission. The potential influencing factors of APOs in pregnant women with PCOS and the predictive value of serum nesfatin-1 and IGF-1 for APOs were analysed. Serum nesfatin-1 and IGF-1 levels were significantly higher in the study group than in the control group (p <0.05). Multivariate analysis revealed that testosterone ≥45μg/L, body mass index ≥25kg/m², waist-hip ratio ≥0.80, gestational diabetes mellitus, nesfatin-1, and IGF-1 were independent risk factors of APOs in patients with PCOS. The AUC for IGF-1 plus nesfatin-1 in predicting APOs in pregnant women with PCOS was 0.900 (95% CI: 0.845, 0.955). Elevated serum nesfatin-1 and IGF-1 levels are associated with pregnancy outcomes of patients with PCOS. Polycystic ovary syndrome, Nesfatin-1, Insulin-like growth factor-1, Adverse pregnancy outcome.

Evaluating the impact of metabolic and cognitive stress on ghrelin and nesfatin-1 hormones in patients with diabetes and diabetic depression.

Nesfatin-1 and ghrelin, initially recognised as hormones involved in regulating energy, have emerged as crucial players with vital functions in various human body systems. In this study, we conducted a comparative assessment of nesfatin-1 and ghrelin responses in individuals experiencing metabolic stress due to diabetes, those with depressive diabetes characterised by both metabolic and mental stress, and healthy controls. We collected blood samples from a total of 90 participants, consisting of 30 people with type II diabetes mellitus (DM), 30 people with type II DM and major depressive disorders, and 30 healthy individuals. Diabetes was diagnosed based on glycated haemoglobin (HbA1c) levels, while depression was assessed using DSM-V criteria. Insulin resistance (HOMA-IR) was calculated, and serum ghrelin and nesfatin-1 levels were measured using ELISA kits. We observed statistically significant decreases in nesfatin-1 and ghrelin levels in the diabetic group (p<0.0001). However, in the depressive diabetic group, nesfatin-1 levels increased significantly, while ghrelin levels decreased further. The nesfatin-1 to ghrelin ratio decreased in the diabetic group but increased significantly in the depressive diabetic group (p<0.0001). Nesfatin-1 and ghrelin hormones exhibit parallel impacts in response to metabolic stress, but nesfatin-1 demonstrates contrasting actions compared to ghrelin when mental stress is added to metabolic stress. The findings of this study suggest that nesfatin-1 and ghrelin hormones may play active roles as protective, prognostic, and even etiological factors in various stress situations, particularly those involving mental stress, in addition to their known functions in regulating energy.

Leptin, Nesfatin-1, Orexin-A, and Total Ghrelin Levels in Drug-Naive Panic Disorder.

This study aimed to examine the changes in serum nesfatin-1, leptin, orexin-A, and total ghrelin levels of patients diagnosed with drug-naive panic disorder (PD) before and after six weeks of the treatment and to compare the findings with the healthy subjects. The neuropeptides were measured in venous blood samples taken from 32 patients and 32 healthy subjects. The blood samples of the patients who used paroxetine 20 mg/day plus alprazolam 0.5 mg/day were retaken again after six weeks. Measurements were performed with the Enzyme-Linked Immunosorbent Assay (ELISA) method. Serum nesfatin-1, leptin, orexin-A and total ghrelin levels of the patient group were found to be significantly lower than the control group (p<0.001, p<0.001, p<0.001, and p<0.001, respectively). When the serum nesfatin-1, leptin, orexin-A and total ghrelin levels of the patient group were compared before and after treatment, significant differences were found in terms of orexin-A and total ghrelin levels (p=0.046, p<0.001, respectively). However, no significant differences were found in terms of nesfatin-1and leptin levels (p=0.205, p=0.988, respectively). This study reports that PD, like other anxiety disorders, may affect serum nesfatin-1, leptin, orexin-A, and total ghrelin levels, and there may be a relationship between PD treatment and the levels of these neuropeptides. The variability of this relationship among the neuropeptides examined indicates that various factors other than treatment play a role in this process.

Blood nesfatin-1 levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis.

Previous studies have investigated the relationship between nesfatin-1 level and polycystic ovary syndrome (PCOS). However, these studies have produced conflicting results. Thus, in this meta-analysis, we aimed to clarify the association between blood nesfatin-1 levels and PCOS, and the ability of nesfatin-1 as a biomarker in PCOS. Meta-analysis was performed using STATA 12.0 software. We computed standard mean difference (SMD) and 95% confidence interval (CI) regarding the comparison of blood nesfatin-1 in patients with PCOS and controls. The present meta-analysis showed no significant difference in blood nesfatin-1 level between patients with PCOS and controls with a random effects model (SMD = 0.03; 95%CI: -0.71, 0.77; I2 = 97.1%, p value for Q test < 0.001). Subgroup analysis for different ethnicities reported no significant difference in blood nesfatin-1 level between patients with PCOS and controls in both Caucasian and Asian populations. Subgroup analysis for different sample types reported no significant difference in serum nesfatin-1 level between patients with PCOS and controls. Subgroup studies reported no significant difference in blood nesfatin-1 level between PCOS and controls in both obese and non-obese populations. In conclusion, there is no significant relationship between blood nesfatin-1 levels and PCOS.

Ассоциация уровня несфатина 1 с показателями композитного состава тела у пациентов с ревматоидным артритом

Aim. To study the association of serum nesfatin 1 (NF-1) levels with body mass index (BMI), body composition and rheumatic cachexia (RC). Design. Cross-sectional comparative study. Materials and methods. 110 patients with rheumatoid arthritis (RA) and 60 healthy controls were enrolled in our study. Standard clinical and laboratory examination was performed. NF-1 levels were determined with enzyme-linked immunosorbent assay. Each person undergone dual-energy X-ray absorptiometry with Total Body program. Results. Serum NF-1 levels were higher in patients with RA, compared with healthy controls (50.49 ± 34.05 vs 31.61 ± 3.17 ng/ml, t = 4.28; p &lt; 0.0001). RC was determined in 30 patients. In healthy controls, the median level of NF-1 was higher in overweight patients than with normal BMI of class 1 obesity (H = 6.0; p = 0.049). NF-1 in patients with RA correlated with lean mass in legs (separately for the left one), left half of the body, trunk and android region. Median levels of NF-1 in patients were comparable in patients with or without RC. Conclusion. Despite we observed association between serum NF-1 levels and lean tissue mass, this neuroendocrine peptide can’t be used as a marker for RC (Z = 1.45; p = 0.147). Additional studies should be performed to clarify the mechanism of association of NF-1 with lean tissue mass, which would likely contribute to the development of a new approach to controlling this indicator. Keywords: nesfatin 1, rheumatoid arthritis, body composition, body mass index, rheumatic cachexia.

EVALUATION OF THE EFFECT OF SMOKING ON NESFATIN-1 LEVEL

Aim: Nesfatin-1 is a recently discovered adipocytokine that is believed to regulate food intake and is linked to body mass index. While its precise mechanism of action remains unclear, a deeper understanding of how nesfatin-1 interacts with metabolic diseases, inflammation, and insulin resistance could have significant implications for the treatment of a wide range of conditions, including cardiovascular disease. &#x0D; Smoking is a complex issue with roots in social, cultural, and economic factors that can contribute to nicotine addiction. Additionally, nicotine's ability to stimulate the mind and promote feelings of relaxation can create a positive feedback loop that makes it difficult to quit. Unfortunately, there is limited research on the effects of smoking on Nesfatin-1 levels. However, one study found that women who smoke tend to have lower levels of Nesfatin-1. To build on this finding, the present study aims to further investigate nesfatin-1 levels in both smokers and non-smokers.&#x0D; Methods: A total of 70 participants, smokers (n=35) and non-smokers (n=35), were included in the study. The participant's gender, age, height and weight, body mass index, and nesfatin-1 levels were measured and compared.&#x0D; &#x0D; The SPSS 23.0 program was used to evaluate the data statistically. Data were evaluated with a t-test. The error level was taken as 0.05.&#x0D; &#x0D; Result: Serum Nesfatin-1 levels were significantly higher in smokers (13.73± 3.11) than in non-smokers (8.63 ± 0.91) (t=-9.315, p&amp;lt;0.01). No significant difference was found between other parameters in the smoker and non-smoker groups.&#x0D; &#x0D; Conclusion: Our study has shown that individuals who smoke display higher levels of Nesfatin-1 compared to non-smokers, indicating a correlation between smoking and Nesfatin-1. However, further investigation is required to understand the mechanism behind this increase. It is hoped that continued research will unveil the potential of Nesfatin-1 in treating human obesity.

Nesfatin-1 protects the reproductive health of male Sprague Dawley rats exposed to blue and white LED lights

There is little information on the effects of exposure to light emitting diode (LED) illumination on the welfare of laboratory animals. Nesfatin-1, a satiety-regulation peptide present in various tissues, is found in the central nervous system and participates in the stress response. The present study investigated whether exposure to blue and white LED lights for 14 weeks affected growth and reproductive, biochemical and histopathological parameters in male Sprague Dawley (SD) rats as well as whether subcutaneous (SC) injection of nesfatin-1 (0.5 mg/kg bodyweight) in the last two weeks of the experimental period alleviated these effects. Forty male SD rats (21 days of age) were randomly allotted to 6 groups. The animals were exposed to routine fluorescent light (the control [C] and control + sesame oil [CS] groups) or blue/white LEDs (the blue-LED and white-LED groups), accompanied by nesfatin-1 administration (the blue-LED-N1 and white-LED-N1 groups). White-LED rats had significantly higher testis weights (p < 0.05) than control and blue-LED rats. Serum melatonin levels were significantly lower in blue-LED rats, but nesfatin-1 injection rescued melatonin levels in blue-LED-N1 rats (p < 0.05). Blue-LED rats showed the highest serum nesfatin-1 levels, but nesfatin-1 injection decreased nesfatin-1 levels in blue-LED-N1 rats (p < 0.0001). Blue-LED rats showed a significant reduction in sperm motility compared to the other groups (p < 0.0001). White and blue LED exposure caused significant negative histopathological changes in the testes, but nesfatin-1 administration reduced edema in the intertubular spaces, hyperemia in the interstitial cells, degeneration of spermatocytes and thinning of the tubular wall in the testicular tissues; these restorative effects were larger in blue-LED-N1 rats than white-LED-N1 rats. Blue and white LED exposures had negative effects on melatonin levels, testis weights and tissue health. Nesfatin-1 alleviated some of the negative effects of LED lighting.

Effects of dietary intervention combined with insulin aspart on serum nesfatin-1 and CTRP12 levels and pregnancy outcomes in pregnant women with gestational diabetes mellitus.

To analyze the effects of dietary intervention combined with insulin aspart on the serum levels of nesfatin-1, C1q/TNF related protein-12 (CTRP12), and pregnancy outcomes in pregnant women with gestational diabetes mellitus (GDM). In this retrospective cohort study, 513 women with GDM admitted to Tangshan Central Hospital (Tangshan, China) between January 2019 and December 2022 were selected and divided into an observation group (dietary intervention combined with insulin aspart therapy; n = 284) and a control group (insulin aspart therapy, n = 229). The general characteristics, clinical outcomes, serum nesfatin-1 and CTRP12 levels, 2-hour postprandial blood glucose levels, pregnancy outcomes, and perinatal outcomes of the 2 groups were compared. After treatment, the total effective rate in the observation group was significantly higher than that of the control group (97.54% vs 86.03%, respectively; P < .001). Compared with the pretreatment levels, nesfatin-1 and CTRP12 levels were decreased in both groups; nesfatin-1 and CTRP12 levels in the observation group were significantly higher than those in the control group. After treatment, the preprandial and 2-hour postprandial blood glucose levels in the observation group were significantly lower than those in the control group. Compared with the control group, the observation group had significantly fewer cesarean sections, and a significantly lower incidence of postpartum hemorrhage, premature rupture of membranes, and other adverse pregnancy outcomes. After treatment, the risks of preterm birth, macrosomia, fetal distress, neonatal asphyxia, neonatal hypoglycemia, and other adverse perinatal outcomes were significantly lower in the observation group than in the control group. In pregnant women with GDM, dietary intervention combined with insulin aspart can improve clinical outcomes; reduce nesfatin-1, CTRP12, and blood glucose levels; and reduce the incidence of adverse pregnancy outcomes.

Aşırı Kilolu/Obez Bireylerde Akupunktur Ve Diyetin Serum Leptin Ve Nesfatin-1 Düzeylerine Etkisi

Acupuncture applications and diet are frequently used in obesity treatment. We aimed to investigate the changes in serum leptin and nesfatin-1 levels measured before and after acupuncture and diet in overweight/obese individuals in the presented study. This interventional study was carried out on 90 overweight/obese patients. Participants were divided into three groups: Group 1 (Acupuncture), Group 2 (Diet), and Group 3 (Those who did not take any attempts to lose weight- control group). Serum leptin and nesfatin-1 levels were measured before and after the intervention. The 30th days leptin values were significantly decreased in the acupuncture group (p=0.040) while they were significantly increased in the control group (p=0.039). It was detected that the nesfatin-1 values were significantly increased in both acupuncture (p=0.032) and diet groups (p=0.017). Also, body weights significantly decreased both in acupuncture (p=0.032) and diet groups (p&amp;lt;0.001). Our results support the effects of acupuncture treatment on appetite hormones. Further research on the mechanisms of endogenous and exogenous actions of the recently discovered hormones, leptin and nesfatin-1, are needed.

Effects of Pinealectomy and Melatonin Application on Serum Melatonin, Nesfatin-1 and Ghrelin Levels

Objective:In this study, it was aimed to investigate the relationship between the pineal gland and ghrelin and nesfatin-1 hormones in rats. Methods: A total of 36 male rats were used in the study, and the animals were divided into 4 groups. Group 1, Control; Group 2, Pinealectomy (Px); Group 3, Px+Melatonin; Group 4 Melatonin. After the end of the experimental applications, melatonin, ghrelin and nesfatin-1 levels (ELISA) were determined in the blood samples taken from the animals. Results: While pinealectomy resulted in suppression of melatonin levels, melatonin supplementation led to a significant increase in blood melatonin levels (p&lt;0.01). Melatonin supplementation suppressed ghrelin levels, while pinealectomy increased ghrelin levels (P&lt;0.01). On the other hand, Nesfatin-1 levels, which increased with melatonin support, were significantly suppressed by pinealectomy (p&lt;0.01). Conclusion: The results of the current study show that the pineal gland may have important effects on the hormones ghrelin and nesfatin-1, which play critical roles in nutrition. In conclusion melatonin supplementation inhibites ghrelin, and but increases nesfatin-1.

Predictive value of nesfatin-1 in heart failure mortality

Abstract Objectives Advanced heart failure is the last stage of heart failure in which the life expectancy of patients is significantly reduced. Many mortality markers have been identified in advanced heart failure. Although the nesfatin-1 molecule is known as a satiety hormone, it has also been shown to be associated with many cardiovascular diseases. This study aims to elucidate the association between in-hospital mortality and nesfatin-1 level in advanced heart failure patients. Methods The research included 74 cases of advanced heart failure. During the coronary intensive care surveillance of these patients, 22 patients had in-hospital mortality. The cases, divided into groups with and without in-hospital mortality, were compared using laboratory data, echocardiography, and demographic properties. Results The age of the cases with in-hospital mortality was older than the cases without mortality [(74 (66–95) vs. 67 (26–90); p=0.019)]. Serum nesfatin-1 level and tricuspid annular plane systolic excursion (TAPSE) were statistically lower in the in-hospital mortality group (43.8 ± 5.5 vs. 40.5 ± 6.1; p=0.027, 13.5 ± 1.9 vs. 16.2 ± 2.6 p=0.001, respectively). Serum nesfatin-1 level and TAPSE were detected as independent predictors for in-hospital mortality in advanced heart failure via multivariate analysis using parameters that were significant in the univariate analysis. Receiver operator characteristic curve analysis showed that the optimum cut-off level for nesfatin-1 in determining in-hospital mortality was ≤23.57 (pg/mL) with a specificity of 73.1 % and a sensitivity of 77.3 % (AUC=0.763, 95 % CI=0.647–0.879, p&lt;0.001). Conclusions This research revealed that in advanced heart failure patients, serum nesfatin-1 amounts are associated with mortality and seem to be an independent predictor of mortality.

A new obesity treatment method that does not require restriction in food intake and organ resection

Background/Aim: There are numerous treatment methods available for obesity, with bariatric surgery being the most effective. However, these techniques come with the risk of serious complications. This study presents a novel obesity treatment device that can shorten the length of the small intestine without the need for surgical intervention. Methods: Our new device comprises three main components: a 25 cm long rope, with one end attached to a 1 cm diameter plastic ring and the other end attached to a 2 mm diameter, 5 g sphere. Twenty-one male Wistar albino rats (6 months old, mean weight 400 g, outbred) were divided into three equal groups. Laparotomy and gastrotomy were performed on the subjects in Group 1, and all three parts of the device were placed into the gastrointestinal tract. In Group 2, only the plastic ring was placed in the stomach, and in Group 3, only a gastrotomy was performed. All subjects were followed for 3 months, during which their body weight, serum ghrelin, leptin, and nesfatin-1 levels were recorded, and the amount of food they consumed was measured. After sacrificing the animals, the stomach, proximal, and distal intestines were resected for histopathological evaluation. Results: The subjects in Group 1 experienced weight loss, whereas those in Groups 2 and 3 showed statistically significant weight gain (P&lt;0.001 and P=0.022, respectively). Serum ghrelin levels were significantly increased in Groups 1 and 3 (P=0.015 and 0.031, respectively), while serum leptin levels were significantly decreased in Group 1 (P=0.015). Plasma nesfatin-1 levels were significantly higher in Group 1 compared to the other groups (P=0.014). There was no statistically significant difference in feed consumption between the groups. Histopathological examination revealed significantly higher fibrosis and inflammation scores in the proximal small intestine of Group 1 compared to the other groups (P=0.008 and P=0.005, respectively). Conclusions: This new device facilitates rapid and effective weight loss without the need for restricting oral food intake or organ resection. Changes in serum ghrelin, leptin, and nesfatin-1 levels did not affect these results. We hypothesize that the effective weight loss is linked to the shortening of the small intestine length. Our future plans involve modifying the device for endoscopic application in humans.

WED-391 - The relation of serum nesfatin-1 levels with disease severity and complications in patients with liver cirrhosis

WED-391 - The relation of serum nesfatin-1 levels with disease severity and complications in patients with liver cirrhosis

Effect of bariatric surgery procedures on serum cytokine and Nesfatin-1 levels

Backgroundand Purpose: Obesity is known to cause chronic inflammation. We aimed to evaluate the changes in Nesfatin-1 and serum cytokine levels of patients who underwent sleeve gastrectomy or gastric bypass surgery. MethodsA total of 30 patients with BMI>35 and undergoing bariatric surgery were divided in two group, sleeve gastrectomy (SG) (group-1), Roux-en-Y gastric bypass (RYGB) (group-2). Demographic data, weight, BMI, AST, ALT, blood glucose, CRP values, and IL-1β, IFN-α, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine, and Nesfatin-1 values were noted at the time of hospitalization and in the 6th month postoperative follow-up. ResultsThe mean age of the patients was 37.56 ± 11.73 years, and there were 16 females and 14 males in the study. Body weight and excess body weight change were slightly higher in RYGB patients than in SG patients. In RYGB and SG patients, a significant decrease was found in glucose, AST, ALT, CRP, IL-6, IL-10, and IL-18 values compared to the preoperative period, and serum Nesfatin-1 levels were significantly increased in RYGB patients and not significantly in SG patients. There were also significant decreases in IL-1β levels in RYGB patients. On the other hand, a decrease in cytokines was observed in both surgical methods, except for IL-17A, although it was not significant. ConclusionThe present study showed that there is also a regression in inflammation, which can be associated with NLRP3 inflammasome, due to weight loss after bariatric surgery, more specifically in RYGB.

NESFATIN-1 ACTIVITY IN THE BLOOD SERUM IN PATIENTS WITH CHRONIC HEART FAILURE OF ISCHEMIC ORIGIN AGAINST THE BACKGROUND OF TYPE 2 DIABETES MELLITUS AND OBESITY.

The aim: To study the nesfatin-1 activity in the blood serum of patients with chronic heart failure (CHF) of ischemic origin against the background of such metabolic disorders as type 2 diabetes mellitus (T2DM) and obesity. Materials and methods: 154 patients with CHF were examined, and divided into 4 groups, according to the presence of metabolic disorders. Group 1 included patients with CHF on the background of coronary heart disease (CHD) and T2DM and obesity (n=42). The second group consisted of patients with heart failure on the background of CHD with concomitant T2DM (n=46), the third group - with concomitant obesity (n=36), the fourth group was formed from patients with signs of heart failure of ischemic origin without metabolic disorders (n=30). The control group (CG) included 30 practically healthy persons of comparable age. Results: The mean level of serum nesfatin-1 was 1.64±0.27 ng/mL in the СHF group, 0.342±0.19 ng/mL in the CHF + T2DM + obesity group, 1.06±0.36 ng/ mL in the obese + CHF group, 0.96±0.27 ng/mL in the CHF + T2DM group and 2.98±0.38 ng/mL in the CG. Significant correlation was found between the serum nesfatin-1 level and BMI (r=-0.34, p<0.05), HOMA (r=-0.54, p<0.05), insulin (r=-0.41, p<0.05). No significant correlation was found between the serum nesfatin-1 level and blood glucose level (r=0.13, p=0.65). Conclusions: Thus, nesfatin-1 may play a significant role in the pathogenesis of both weight-related abnormalities and type 2 diabetes mellitus in patients with chronic heart failure of ischemic origin.

The effects of different fatty acids on nesfatin-1, omentin-1, adropin, leptin and ghrelin levels

There are many studies on nesfatin-1, omentin, adropin, leptin, and ghrelin. However, data on the effects of long, medium, and short chain fatty acids on serum/tissue concentrations of nesfatin-1, omentin, adropin, leptin, and ghrelin are scarce. This study aims to investigate the effects of butyric acid, caprylic acid, and oleic acid alone or in combination on nesfatin-1, omentin, adropin, leptin, and ghrelin secretion. In the study, 49 male Wistar rats were used. The rats were randomly divided into 7 groups as control (CONT), butyric acid (BA), caprylic acid (CA), oleic acid (OA), butyric acid+caprylic acid (BA+CA), butyric acid+oleic acid (BA+OA) and caprylic acid+oleic acid (CA+OA) groups. The rats were orally administered fatty acids for twenty-one days. At the end of the study, the levels of nesfatin-1, omentin, adropin, leptin, and ghrelin were determined by the ELISA method. When the groups were compared in terms of nesfatin-1, omentin, adropin, leptin, and ghrelin levels, the butyric acid group had higher nesfatin-1, omentin, adropin, leptin, and ghrelin levels than the other groups (p&lt;0.05). No statistically significant difference was found in the other groups (p&gt;0.05). In conclusion, it was observed that butyric acid use caused an increase in serum nesfatin-1, omentin, adropin, leptin, and ghrelin levels.

Nesfatin-1 in Human Milk and Its Association with Infant Anthropometry.

Breastfed infants have different growth patterns to formula-fed infants and are less likely to develop obesity later in life. Nesfatin-1 is an anorexigenic adipokine that was discovered in human milk more than a decade ago, and its role in infant appetite regulation is not clear. Our aim was to describe nesfatin-1 levels in human milk collected 3-4 months postpartum, associations with infant anthropometry, and factors (maternal pre-pregnancy body mass index (mBMI), high weight gain during pregnancy, milk fat, and energy content) possibly influencing nesfatin-1 levels. We hypothesized that nesfatin-1 levels in mother's milk would differ for infants that were large (high weight-for-age Z-score (WAZ)) or small (low WAZ) at the time of milk sample collection. We used enzyme-linked immunosorbent assay to detect the nesfatin-1 concentration in milk samples from mothers to high WAZ (n = 50) and low WAZ (n = 50) infants. We investigated associations between nesfatin-1 levels and infant anthropometry at 3-4 months of age and growth since birth, using linear regression adjusted for mBMI, birth weight, infant sex, and exclusivity of breastfeeding. We found no difference in nesfatin-1 levels between the two groups and no association with infant anthropometry, even after adjusting for potential confounders. However, high nesfatin-1 levels were correlated with low mBMI. Future research should investigate serum nesfatin-1 level in both mothers, infants and associations with growth in breastfed children.

The role of serum nesfatin-1 in a rat model of acute pancreatitis.

Acute pancreatitis (AP) is a disease that can still be fatal despite rapid advances in medicine. The relationship between serum nesfatin-1 levels and AP is still to be fully resolved. To investigate the utility of serum nesfatin-1 levels in the diagnosis of AP. Twenty-four male Sprague Dawley rats were divided into control, mild pancreatitis and severe pancreatitis groups (n = 8/group). Acute pancreatitis was induced by cerulein injection and the control group received saline injections. Then, the serum nesfatin-1, amylase, lipase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were determined. A pathologist blinded to the study scored the severity of pancreatitis. There was a considerable decrease in serum nesfatin-1 levels in parallel to the severity of pancreatitis, though there was no statistically significant relationship observed between pancreatitis and nesfatin-1. In addition, there was no significant difference in AST or ALT levels among the groups. However, a strong positive correlation between amylase and lipase levels was observed (p < 0.05). The severe pancreatitis group (group 3) had a higher lipase level and pathology score than mild pancreatitis group (group 2), and this difference was statistically significant. Serum nesfatin-1 may be used as a diagnostic and severity marker in pancreatitis in the future.

Influence of circulating nesfatin-1, GSH and SOD on insulin secretion in the development of T2DM.

AimsTo evaluate the correlation of nesfatin-1, GSH and SOD levels with β-cell insulin secretion and their influence on insulin secretion in the development of type 2 diabetes mellitus (T2DM).Materials and methods75 patients with T2DM, 67 with prediabetes and 37 heathy participants were recruited in this study. Serum levels of nesfatin-1, GSH and SOD were quantified and statistically analyzed.ResultsThe levels of nesfatin-1, GSH and SOD in T2DM were significantly decreased (P < 0.001) compared to either in prediabetes or in healthy control, and significant reduction of these biomarkers was also observed in prediabetes when compared to the control (P < 0.001). Circulating nesfatin-1, GSH and SOD were not only strongly correlated with β-cell insulin secretion, but also exerted remarkable influence on the secretion.ConclusionSerum nesfatin-1, GSH and SOD are important factors involving insulin secretion in the development of T2DM, which may help provide new ideas for forthcoming investigations on the roles of these factors in pathogenesis of T2DM, as well as for active prediction and prevention of prediabetes before it develops into overt T2DM.